68Ga-PSMA PET/CT在胆管癌中的应用:靶向放射性配体治疗的潜在生物标志物?
提示胆管癌转移灶PSMA表达可能为α/β发射体放射性配体治疗提供依据。
要点
- PSMA在多种实体瘤新生血管内皮表达,可能与肿瘤相关血管生成因子有关
- PSMA表达可能指导胆管癌的放射性配体治疗选择
核心结论
- 胆管癌转移灶可表达PSMA,68Ga-PSMA PET/CT有望作为靶向放射性配体治疗的潜在生物标志物。
主要发现
- 原文指出PSMA在多种实体恶性肿瘤新生血管内皮表达,可能与肿瘤相关血管生成因子及内皮细胞出芽有关。
临床怎么用
- 对化疗进展、已无其他获批治疗选择的胆管癌患者,可考虑68Ga-PSMA PET/CT评估PSMA表达,为α/β发射体放射性配体治疗提供依据。
局限性
- 原文为单例个案报道,未提供样本量、随访及治疗结局等数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ga-PSMA is a promising tracer for both staging and detection of biochemical recurrence in prostate cancer. Prostate-specific membrane antigen is also expressed in the endothelium of neovasculature of various solid malignancies possibly due to tumor-associated angiogenic factors and endothelial cell sprouting. We report a case of 75-year-old man with metastatic cholangiocarcinoma to liver and lymph nodes progressing on chemotherapy. Ga-PSMA PET/CT was performed to assess PSMA expression and showed additional bone and hepatic lesions compared with F-FDG PET/CT. Ga-PSMA expression in the metastatic cholangiocarcinoma potentially guides radionuclide legend therapy with α/β-emitters especially after enervation of all approved therapeutic options.
引用
- Marafi F, Usmani S, Esmail A, et al. 68Ga-Prostate-Specific Membrane Antigen PET/CT in Cholangiocarcinoma: A Potential Biomarker for Targeted Radioligand Therapy? Clin Nucl Med. 2019. PMID: 30985434. doi:10.1097/RLU.0000000000002563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。